Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation - PubMed (original) (raw)
. 2004 Oct;84(10):1289-304.
doi: 10.1038/labinvest.3700159.
Yoshio Naomoto, Munenori Takaoka, Tetsuji Nobuhisa, Kazuhiro Noma, Takayuki Motoki, Toshihiro Murata, Hirokazu Uetsuka, Masahiko Kobayashi, Yasuhiro Shirakawa, Tomoki Yamatsuji, Nagahide Matsubara, Junji Matsuoka, Minoru Haisa, Mehmet Gunduz, Hidetsugu Tsujigiwa, Hitoshi Nagatsuka, Masao Hosokawa, Motowo Nakajima, Noriaki Tanaka
Affiliations
- PMID: 15286661
- DOI: 10.1038/labinvest.3700159
Free article
Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation
Takaomi Ohkawa et al. Lab Invest. 2004 Oct.
Free article
Abstract
In this study, we examined the distribution of heparanase protein in 75 esophageal squamous cell carcinomas by immunohistochemistry and analyzed the relationship between heparanase expression and clinicopathological characteristics. In situ hybridization showed that the mRNA expression pattern of heparanase was similar to that of the protein, suggesting that increased expression of the heparanase protein at the invasive front was caused by an increase of heparanase mRNA in tumor cells. Heparanase expression correlated significantly with depth of tumor invasion, lymph node metastasis, tumor node metastasis (TNM) stage and lymphatic invasion. Overexpression of heparanase in esophageal cancers was also associated with poor survival. In addition to its localization in the cytoplasm and cell membrane, heparanase was also identified in the nuclei of normal epithelial and tumor cells by immunohistochemistry. Furthermore, nuclear heparanase was detected in nuclear extract of cancer cell lines by Western blot and immunohistochemistry. Examination of the role of nuclear heparanase in cell proliferation and differentiation by double immunostaining for proliferating cell nuclear antigen (PCNA) and cytokeratin 10 (CK10) showed significant relationship between nuclear heparanase expression and differentiation (heparanase vs CK10), but not for proliferative state of esophageal cancer cells (heparanase vs PCNA). Our results suggest that cytoplasmic heparanase appears to be a useful prognostic marker in patients with esophageal cancer and that nuclear heparanase protein may play a role in differentiation. Inhibition of heparanase activity may be effective in the control of esophageal tumor invasion and metastasis.
Similar articles
- Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M, Nakajima M, Nakamura K, Koike M. Mikami S, et al. Jpn J Cancer Res. 2001 Oct;92(10):1062-73. doi: 10.1111/j.1349-7006.2001.tb01061.x. Jpn J Cancer Res. 2001. PMID: 11676857 Free PMC article. - Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis.
Beckhove P, Helmke BM, Ziouta Y, Bucur M, Dörner W, Mogler C, Dyckhoff G, Herold-Mende C. Beckhove P, et al. Clin Cancer Res. 2005 Apr 15;11(8):2899-906. doi: 10.1158/1078-0432.CCR-04-0664. Clin Cancer Res. 2005. PMID: 15837740 - Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.
Okawa T, Naomoto Y, Nobuhisa T, Takaoka M, Motoki T, Shirakawa Y, Yamatsuji T, Inoue H, Ouchida M, Gunduz M, Nakajima M, Tanaka N. Okawa T, et al. Clin Cancer Res. 2005 Nov 15;11(22):7995-8005. doi: 10.1158/1078-0432.CCR-05-1103. Clin Cancer Res. 2005. PMID: 16299228 - Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S, Wang Z, Huang J, Cheng S, Du H, Che G, Peng Y. Li S, et al. BMC Cancer. 2016 Nov 11;16(1):877. doi: 10.1186/s12885-016-2940-7. BMC Cancer. 2016. PMID: 27835987 Free PMC article. Review. - The role of heparanase in gastrointestinal cancer (Review).
Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz M, Tanaka N. Naomoto Y, et al. Oncol Rep. 2005 Jul;14(1):3-8. Oncol Rep. 2005. PMID: 15944760 Review.
Cited by
- Heparanase and hepatocellular carcinoma: promoter or inhibitor?
Dong S, Wu XZ. Dong S, et al. World J Gastroenterol. 2010 Jan 21;16(3):306-11. doi: 10.3748/wjg.v16.i3.306. World J Gastroenterol. 2010. PMID: 20082475 Free PMC article. Review. - Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer.
Xie ZJ, Liu Y, Jia LM, He YC. Xie ZJ, et al. World J Gastroenterol. 2008 Jun 28;14(24):3812-8. doi: 10.3748/wjg.14.3812. World J Gastroenterol. 2008. PMID: 18609704 Free PMC article. - Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.
Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Doweck I, et al. Neoplasia. 2006 Dec;8(12):1055-61. doi: 10.1593/neo.06577. Neoplasia. 2006. PMID: 17217623 Free PMC article. - Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.
Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I. Cohen-Kaplan V, et al. Int J Cancer. 2008 Dec 1;123(11):2566-73. doi: 10.1002/ijc.23898. Int J Cancer. 2008. PMID: 18798279 Free PMC article. - Heparanase: A Dynamic Promoter of Myeloma Progression.
Purushothaman A, Sanderson RD. Purushothaman A, et al. Adv Exp Med Biol. 2020;1221:331-349. doi: 10.1007/978-3-030-34521-1_12. Adv Exp Med Biol. 2020. PMID: 32274716 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous